Hypolipidemic activity of 3-amino-1-(2,3,4-mononitro-, mono-, or dihalophenyl) propan-1-ones in rodents

Archiv der Pharmazie

Volumn 329, Issue 7, 1996, Pages 339-346

  Huang, Yunsheng ^a   Hall, Iris H ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

3 amino 1 (2,3,4 mononitro , mono , or dihalophenyl)propan 1 ones; cholesterol levels; HDL; LDL; triglyceride levels; VLDL

Indexed keywords

3 MORPHOLINO 1 (3 NITROPHENYL) 1 PROPANONE; 3 PIPERIDINO 1 (3 NITROPHENYL) 1 PROPANONE; ANTILIPEMIC AGENT; CHOLESTEROL; CHYLOMICRON; CLOFIBRATE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MEVINOLIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; DRUG SYNTHESIS; ENZYME ACTIVITY; HYPERLIPIDEMIA; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ANTILIPEMIC AGENTS; CHOLESTEROL; ENZYME INHIBITORS; HYPERLIPIDEMIAS; KETONES; LIVER; MALE; MICE; RATS; RATS, SPRAGUE-DAWLEY; TRIGLYCERIDES;

EID: 0030017559     PISSN: 03656233     EISSN: None     Source Type: Journal    
DOI: 10.1002/ardp.19963290703     Document Type: Article

References (23)

1. Y. Huang, Iris H. Hall, Eur. J. Med. Chem. 1996, 31, 281-290.
2. Y. Huang, Iris H. Hall, Die Pharmazie. 1996, 51, 199-206.
3. A.T. Ness, J.V. Pastewka, A.C. Peacock, Clin. Chim. Acta 1964, 10, 229-237.
4. T.C. Huang, C.P. Chen, V. Wefler, A. Raftery, Anal. Chem. 1961, 33, 1405-1407.
5. M.W. McGowan, J.D. Artiss, D.R. Strandbergh, B. Zak, Clin. Chem. 1983, 29, 538-542.
6. J. Folch, M. Lees, G.H.L. Stanley, J. Biol. Chem. 1957, 226, 497-509.
7. E.G. Bligh, W.J. Dyer, Can. J. Biochem. Physiol. 1958, 37, 911-917.
8. J.H. Bragdon, J. Biol. Chem. 1951, 190, 513-517.
9. C.P. Stewart, E.G. Hendry, Biochem. J. 1935, 29, 1683-1689.
10. O.H. Lowry, W.J. Rosebrough, A.L. Farr, R.J. Randall, J. Biol. Chem. 1951, 193, 265-275.
11. F.T. Hatch, R.S. Lees, Adv. Lipid Res. 1968, 6, 1-68.
12. R.J. Havel, A.A. Eder, J.H. Bragdon, J. Clin. Invest. 1955, 34, 1345-1353.
13. I.H. Hall, O.T. Wong, S.D. Wyrick, Pharm. Res. 1988, 5, 413-420.
14. A.G. Goodridge, J. Biol. Chem. 1973, 248, 4318-4326.
15. G. Hoffman, L. Weiss, O. Weiland, Anal. Biochem. 1978, 84, 441-448.
16. S. Shefer, S. Hauser, E.M. Mosbach, J. Lipid Res. 1968, 9, 328-333.
17. S. Balasubramaniam, K.A. Mitropoulos, S. Venkatesan, Eur. J. Biochem. 1978, 90, 377-383.
18. G.T. Haven, J.R. Krzemein, T.T. Nguyen, Res. Comm. Chem. Path. Pharmacol. 1973, 6, 253-262.
19. F. Wada, K. Hirata, Y. Sakamoto, J. Biochem. (Tokyo) 1969, 65, 171-175.
20. M.D. Greenspan, J.W. Lowenstein, J. Biol. Chem. 1968, 243, 6273-6280.
21. R.G. Lamb, S.D. Wyrick, C. Piantadosi, Atherosclerosis 1977, 27, 147-154.
22. R.D. Mavis, J.N. Finkelstein, B.P. Hall, J. Lipid Res. 1978, 19, 467-477.
23. A. Chait, P.H. Iverius, J.D. Brunzel, J. Clin. Invest. 1982, 69, 460-493.